The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial
Lühua Wang(The University of Texas MD Anderson Cancer Center), André Goy(Rutgers, The State University of New Jersey), Peter Martin(NewYork–Presbyterian Hospital), Lauren S. Maeda(Stanford Medicine), Kristie A. Blum(The Ohio State University), Simon Rule(University Hospitals Plymouth NHS Trust), Ranjana H. Advani(Stanford University), Sara Rodríguez(Navarre Institute of Health Research), Brad S. Kahl(UW Health University Hospital), Ching-Fai Pang(Pharmacyclics (United States)), Michael E. Williams(University of Virginia), Eric Hedrick(Biogen (United States))
Cited by 41
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
|New England Journal of Medicine|2018|1.1k